{"id":"NCT00627926","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"A Phase 3 Study of Telaprevir in Combination With Pegasys速 and Copegus速 in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)","officialTitle":"A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys速) and Ribavirin (Copegus速) in Treatment-Naive Subjects With Genotype 1 Chronic Hepatitis C","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-03","primaryCompletion":"2010-05","completion":"2010-05","firstPosted":"2008-03-04","resultsPosted":"2011-07-21","lastUpdate":"2014-08-08"},"enrollment":1095,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C"],"interventions":[{"type":"BIOLOGICAL","name":"Pegylated Interferon Alfa 2a","otherNames":["Pegasys, Peg-IFN-alfa-2a"]},{"type":"DRUG","name":"Telaprevir","otherNames":["VX-950"]},{"type":"DRUG","name":"Ribavirin","otherNames":["Copegus, RBV"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week","type":"PLACEBO_COMPARATOR"},{"label":"Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week","type":"EXPERIMENTAL"},{"label":"Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week","type":"EXPERIMENTAL"}],"summary":"A Phase 3 study to evaluate the efficacy and safety of two dosing regimens of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV).","primaryOutcome":{"measure":"Number of Subjects Achieving Sustained Viral Response (SVR), Demonstrated by Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels 24 Weeks After Last Planned Dose of Study Treatment","timeFrame":"24 weeks after last planned dose of study treatment (up to Week 72)","effectByArm":[{"arm":"PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week","deltaMin":158,"sd":null},{"arm":"Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week","deltaMin":250,"sd":null},{"arm":"Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week","deltaMin":271,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":4},"locations":{"siteCount":116,"countries":["United States","Argentina","Australia","Austria","Canada","France","Germany","Israel","Italy","Poland","Puerto Rico","Spain","United Kingdom"]},"refs":{"pmids":["21696307"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":24,"n":361},"commonTop":["fatigue","pruritus","headache","nausea","rash"]}}